Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring.
HENDERSON, Nev. , May 11, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic cancers.
The study was led by Dr. Heather Wilson-Robles, a leading veterinary oncologist and Chief Medical Officer at Volition Veterinary, and took place at the Small Animal Clinical Sciences Department at Texas A&M University. The team used Volition's nucleosome quantification technology, the Nu.Q® Vet Cancer Test, for the study.
Cancers that begin in blood-forming tissue, such as bone marrow or in the cells of the immune system, are common in dogs and represent almost a third of malignancies diagnosed each year.
Dr. Heather Wilson-Robles said:
"Veterinarians typically rely on physical exam findings, radiographs, ultrasound, and baseline blood work to monitor dogs with hematopoietic cancers for treatment response and remission status. However, to date, there has been a lack of useful circulating biomarkers available in veterinary medicine.
"We evaluated circulating plasma nucleosome concentrations at diagnosis, throughout treatment and during remission monitoring for 40 dogs with lymphoma, acute myelogenous leukemia, and multiple myeloma. C-reactive protein and thymidine kinase-1 levels were also recorded."
Dr. Wilson Robles continued: "We found that plasma nucleosome concentrations were significantly higher at diagnosis and progressive disease than they were when dogs were in remission. The study also showed that nucleosome concentrations nearly always returned to the low range during treatment and are associated with clinical remission. In addition, nucleosome elevations often recur at the time of disease progression, mirroring the clinical course of the disease and that higher nucleosome levels are inversely correlated with survival."
The findings also show that plasma nucleosome concentrations correlated better with disease response and progression than either thymidine kinase or C-reactive protein.
Volition's Nu.Q® Vet Cancer Test is a reliable and affordable screening tool for dogs with increased risk of developing cancer, that can be easily integrated into preventive care plans. This same test can now also be used as an innovative monitoring tool for canine lymphoma management. For more details go to: www.volition.com
- "Monitoring plasma nucleosome concentrations to measure of disease response and progression in dogs with hematopoietic malignancies." Dr Heather Wilson-Robles et al, PLOS ONE April 2023
Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. The website address is included in this document as an inactive textual reference only.
Louise Batchelor/Debra Daglish, Volition, firstname.lastname@example.org +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the timing and launch of product sales, and the potential uses, benefits and effectiveness of its Nucleosomics™ technology platform, including the Nu.Q® Vet Cancer Test. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition's, Nu.Q® Vet Cancer Test or other products based on its Nucleosomics™ platform; Volition's failure to secure adequate intellectual property protection; Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-study-shows-nucleosome-concentrations-are-a-useful-tool-for-canine-cancer-treatment-monitoring-301822055.html
SOURCE VolitionRx Limited